Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 46.90p 47.00p 48.50p - - - 0 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -7.2 -4.5 - 96.00

Futura Medical Share Discussion Threads

Showing 16751 to 16774 of 17075 messages
Chat Pages: Latest  671  670  669  668  667  666  665  664  663  662  661  660  Older
DateSubjectAuthorDiscuss
07/5/2019
10:29
Market cap of 60 million (28p sp) ist still a PURE GIFT for this company Market cap 60 million /Cash 10.5 million / Potency Drug with 2 BILLION Market potential close to Phase 3 readout /CSD500 Condom approved in Europe and many Countries outside of Europa + more Approvals & Licensing deals coming / TPR100 (Topical Gel for Pain ) first approval expected next Quarter = POTENTIAL 10++ BAGGER GEM Futura Medical featured in Growth Company Investor recommendations 08 January 2019 CEO James Barder describes Futura as a medtech rather than biotech business. Its proprietary technology is DermaSys which delivers drugs rapidly through the skin and into the blood system. The lead product is MED2005 which is a topical gel for erectile dysfunction. The main advantage over Viagra is that it takes effect within five minutes, compared with over an hour for the famous blue pills. Which ensures key ingredients of spontaneity and mood can be retained while the treatment works. Research suggests a 20% market share could be possible, equating to sales of $560m in major western markets. In time an OTC version could more than double this.
ih_635590
06/5/2019
20:31
htTps://www.pharmaceutical-technology.com/features/new-treatments-erectile-dysfunction/ htTps://bigdeal.ft.com/videos/big-pharmas-billion-dollar-bets/ htTps://www.spiked-online.com/2019/02/14/three-cheers-for-new-viagra/ Fum is gettting attention, the gel works, advance stages in testing higher dosages, FUM state high chance of success. Sure a takeover targer. House Broker thinks they can take 20% market share in the ED market. One to watch for 2019.
neo26
04/5/2019
20:29
GlaveyMaybe news on regulatory approval of the pain relief gel which was submitted last July..
neo26
04/5/2019
04:54
Wasn't you I was worried about J777J, it was the others. How are they going to cope with all the fortune you are bringing to their tables? neo26. Who knows, it could be GSK or RB interested... RNS soon?
glavey
03/5/2019
17:27
All going well here!
ny boy
03/5/2019
16:38
but then... ZEN moved yesterday and the next day a placing out of the blue. Aim is getting very suspect recently... FUM have said they have enough funding till the end of phase 3 trials, we also have a large ii selling. We will soon find out whats happening, mkt cap for a stock like this looks cheap btw.
neo26
03/5/2019
16:17
i am intrigue the current week it has increased, something is happening. Take over offer would be nice. They have a good drug, particularly for people who a diabetic, i hear some find it difficult to get an erection.
neo26
03/5/2019
16:15
ayesha lol
neo26
03/5/2019
16:03
Massive chart break out for starters.He didn't get the memo.
j777j
03/5/2019
15:56
Be careful. There is no news to support this.
ayesha4
03/5/2019
13:45
It will be if the drug works
kop202
03/5/2019
13:44
Share price firming up nicely
kop202
03/5/2019
13:25
Wonder if there is news out there not yet made public, this is a remarkable rise.
rrr
03/5/2019
13:17
Difficult to buy stock! Was only offered 5000 shares at 25, had to pay 25.5 for 20000.
wantage
03/5/2019
13:11
The chart speaks volumes !!! No pun intended
akmal101
03/5/2019
12:39
Volume and price spike!
andyj
03/5/2019
12:34
This is roaring!
mirabeau
03/5/2019
11:59
These were trading at 90p a couple of years back. This time around we are months away from a possible blockbuster drug.
j777j
03/5/2019
11:42
What is interesting is that thus far there has been no RNS relating to a change in share holdings,in particular Lombard's holding.I hope that I am not speaking to soon,but this must be a positive.
martinelwick
03/5/2019
10:03
Definitely one to hold long term
akmal101
03/5/2019
07:46
The global topical pain relief market is much bigger than the ED market and with rapidly ageing populations, is set for continued strong growth. FUM have another potential huge winner in this sector. Eye watering potential when you combine the ED and Pain relief market sizes. Not long now.
j777j
02/5/2019
16:47
From Futura website re TPR100: "A marketing authorisation filing was submitted by Thornton and Ross in July 2018 and await responses and action from the UK regulator."
rrr
02/5/2019
16:45
Not new, just a reminder: hTTp://www.thorntonandross.co.uk/newsPage.aspx?from=Futura "Thornton & Ross Ltd sign licensing agreement for novel pain relief gel Thornton & Ross (T&R) are pleased to announce they have entered in to a long-term licensing agreement with Futura Medical, specialists in transdermal drug technology, for their novel topical diclofenac gel, TPR100. Under the terms of the agreement, Thornton & Ross will conduct the manufacturing scale-up of TPR100 and hold rights to manufacture, market and distribute the product in the UK for the lifetime of the product's patents, which run to at least 2028 in the UK. TPR100, which benefits from the rapid skin permeation rates offered by Futura's proprietary DermaSys® delivery system, demonstrated statistically significant results in a 2015 clinical study comparing the product against both placebo and currently marketed products. Dieno George, Executive Vice President of Brands at STADA, said: "Thornton & Ross is an ideal partner for Futura, with its expertise in both OTC and Rx marketing and we are very excited to bring TPR100 into our product portfolio. TPR100's topical formulation, and positive trial results achieved to date, mean that it has the potential to be a product that very successfully meets patient needs." Barry Draude, Managing Director at T&R, said: "Thornton & Ross are always seeking innovative technology that brings real benefits to patients and consumers and Futura's TPR100 is an excellent example of this. Futura are experts in topical pain relief and we look forward to working with them and to bringing this exciting product to market""
rrr
02/5/2019
12:31
More interested in when the US funds start buying.May have started,good volumes, time will tell.
j777j
Chat Pages: Latest  671  670  669  668  667  666  665  664  663  662  661  660  Older
Your Recent History
LSE
FUM
Futura Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190718 06:42:12